CREBBP mutation
|
Diffuse Large B Cell Lymphoma
|
CREBBP mutation
|
Diffuse Large B Cell Lymphoma
|
ibrutinib Sensitive: C3 – Early Trials
|
ibrutinib Sensitive: C3 – Early Trials
|
CREBBP mutation
|
CRC
|
CREBBP mutation
|
CRC
|
Immunotherapy Sensitive: C3 – Early Trials
|
Immunotherapy Sensitive: C3 – Early Trials
|
CREBBP mutation
|
CRC
|
CREBBP mutation
|
CRC
|
Immunotherapy Sensitive: C3 – Early Trials
|
Immunotherapy Sensitive: C3 – Early Trials
|
CREBBP mutation
|
Diffuse Large B Cell Lymphoma
|
CREBBP mutation
|
Diffuse Large B Cell Lymphoma
|
R-CHOP Sensitive: C3 – Early Trials
|
R-CHOP Sensitive: C3 – Early Trials
|
CREBBP mutation
|
Bladder Cancer
|
CREBBP mutation
|
Bladder Cancer
|
Immunotherapy Sensitive: C3 – Early Trials
|
Immunotherapy Sensitive: C3 – Early Trials
|
CREBBP mutation
|
Follicular Lymphoma
|
CREBBP mutation
|
Follicular Lymphoma
|
YF2 Sensitive: D – Preclinical
|
YF2 Sensitive: D – Preclinical
|
CREBBP mutation
|
Triple Negative Breast Cancer
|
CREBBP mutation
|
Triple Negative Breast Cancer
|
CDK6 inhibitor Sensitive: D – Preclinical
|
CDK6 inhibitor Sensitive: D – Preclinical
|
CREBBP mutation
|
Triple Negative Breast Cancer
|
CREBBP mutation
|
Triple Negative Breast Cancer
|
CDK4 inhibitor Sensitive: D – Preclinical
|
CDK4 inhibitor Sensitive: D – Preclinical
|